Vertex Pharmaceuticals (VRTX) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Vertex Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$9.84B

Latest Revenue (Q)

$2.77B

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

Vertex Pharmaceuticals Revenue by Period

Vertex Pharmaceuticals Revenue by Year

Date	Revenue	Change
2023-12-31	$9.84B	10.17%
2022-12-31	$8.93B	17.91%
2021-12-31	$7.57B	22.06%
2020-12-31	$6.21B	49.07%
2019-12-31	$4.16B	36.59%
2018-12-31	$3.05B	22.46%
2017-12-31	$2.49B	46.20%
2016-12-31	$1.70B	64.89%
2015-12-31	$1.03B	77.86%
2014-12-31	$580.41M	-52.11%
2013-12-31	$1.21B	-20.63%
2012-12-31	$1.53B	8.25%
2011-12-31	$1.41B	883.91%
2010-12-31	$143.37M	40.49%
2009-12-31	$102.05M	-41.85%
2008-12-31	$175.50M	-11.81%
2007-12-31	$199.01M	-8.02%
2006-12-31	$216.36M	34.47%
2005-12-31	$160.89M	56.63%
2004-12-31	$102.72M	48.56%
2003-12-31	$69.14M	-57.08%
2002-12-31	$161.09M	-3.82%
2001-12-31	$167.49M	114.38%
2000-12-31	$78.13M	26.83%
1999-12-31	$61.60M	38.74%
1998-12-31	$44.40M	1.37%
1997-12-31	$43.80M	229.32%
1996-12-31	$13.30M	-39.82%
1995-12-31	$22.10M	12.76%
1994-12-31	$19.60M	-29.75%
1993-12-31	$27.90M	-

Vertex Pharmaceuticals generated $9.84B in revenue during NA 2023, up 10.17% compared to the previous quarter, and up 322.84% compared to the same period a year ago.

Vertex Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2024-09-30	$2.77B	5.21%
2024-06-30	$2.63B	-1.95%
2024-03-31	$2.69B	6.73%
2023-12-31	$2.52B	1.38%
2023-09-30	$2.48B	-0.39%
2023-06-30	$2.49B	4.99%
2023-03-31	$2.37B	3.13%
2022-12-31	$2.30B	-1.35%
2022-09-30	$2.33B	6.29%
2022-06-30	$2.20B	4.71%
2022-03-31	$2.10B	1.20%
2021-12-31	$2.07B	4.46%
2021-09-30	$1.98B	10.64%
2021-06-30	$1.79B	4.01%
2021-03-31	$1.72B	5.93%
2020-12-31	$1.63B	5.82%
2020-09-30	$1.54B	0.90%
2020-06-30	$1.52B	0.62%
2020-03-31	$1.52B	7.21%
2019-12-31	$1.41B	48.79%
2019-09-30	$949.83M	0.91%
2019-06-30	$941.29M	9.65%
2019-03-31	$858.43M	-1.34%
2018-12-31	$870.11M	10.91%
2018-09-30	$784.53M	4.30%
2018-06-30	$752.16M	17.38%
2018-03-31	$640.80M	-1.66%
2017-12-31	$651.63M	12.71%
2017-09-30	$578.16M	6.25%
2017-06-30	$544.13M	-23.87%
2017-03-31	$714.72M	55.81%
2016-12-31	$458.71M	10.86%
2016-09-30	$413.78M	-4.13%
2016-06-30	$431.61M	8.42%
2016-03-31	$398.08M	-4.75%
2015-12-31	$417.94M	34.90%
2015-09-30	$309.82M	86.55%
2015-06-30	$166.08M	19.90%
2015-03-31	$138.51M	-4.18%
2014-12-31	$144.56M	-19.24%
2014-09-30	$178.99M	29.31%
2014-06-30	$138.42M	16.86%
2014-03-31	$118.45M	-66.27%
2013-12-31	$351.16M	58.39%
2013-09-30	$221.70M	-28.66%
2013-06-30	$310.75M	-5.37%
2013-03-31	$328.37M	-1.68%
2012-12-31	$333.99M	-0.60%
2012-09-30	$336.01M	-19.67%
2012-06-30	$418.31M	-4.66%
2012-03-31	$438.74M	-22.12%
2011-12-31	$563.34M	-14.54%
2011-09-30	$659.20M	476.10%
2011-06-30	$114.42M	55.34%
2011-03-31	$73.66M	12.42%
2010-12-31	$65.52M	175.37%
2010-09-30	$23.80M	-24.75%
2010-06-30	$31.62M	40.99%
2010-03-31	$22.43M	-33.82%
2009-12-31	$33.89M	35.79%
2009-09-30	$24.96M	30.91%
2009-06-30	$19.06M	-20.50%
2009-03-31	$23.98M	-26.92%
2008-12-31	$32.81M	3.80%
2008-09-30	$31.61M	-54.46%
2008-06-30	$69.41M	66.55%
2008-03-31	$41.67M	-

Vertex Pharmaceuticals generated $2.77B in revenue during Q3 2024, up 5.21% compared to the previous quarter, and up 111.18% compared to the same period a year ago.

Vertex Pharmaceuticals Revenue Breakdown

Vertex Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
SYMDEKO/SYMKEVI	$123.00M	$180.00M	$420.40M	$628.58M	$1.42B
TRIKAFTA/KAFTRIO	$8.94B	$7.69B	$5.70B	$3.86B	-
KALYDECO	$475.50M	$553.20M	$684.20M	$802.87M	$991.06M
ORKAMBI	$326.00M	$510.70M	$771.60M	$907.51M	$1.33B
Product	$9.87B	$4.16B	-	-	-
Collaborative and Royalty	-	-	$1.00M	$2.90M	$2.10M
TRIKAFTA	-	-	-	-	$420.11M

Vertex Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (50.00%), TRIKAFTA/KAFTRIO (45.32%), KALYDECO (2.41%), ORKAMBI (1.65%), and SYMDEKO/SYMKEVI (0.62%).

Quarterly Revenue by Product

Product/Service	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
TRIKAFTA/KAFTRIO	$2.58B	$2.45B	$2.48B	$2.33B	$2.27B	$2.24B	$2.10B	$2.02B	$2.01B	$1.89B	$1.76B	$1.69B	$1.56B	$1.26B	$1.19B	$1.09B	$960.31M	-	-	-
ORKAMBI	-	-	-	$44.20M	$63.00M	$96.30M	$122.50M	$110.80M	$146.20M	$121.60M	$132.10M	$147.38M	$184.56M	$220.97M	$218.70M	$215.47M	$225.92M	$231.98M	$234.14M	$425.73M
SYMDEKO/SYMKEVI	-	-	-	$27.80M	$33.40M	$31.20M	$30.60M	$34.30M	$38.20M	$42.70M	$64.80M	$80.43M	$81.42M	$133.50M	$125.05M	$127.51M	$156.18M	$171.73M	$173.16M	-
KALYDECO	-	-	-	$112.40M	$112.80M	$125.30M	$125.00M	$136.10M	$139.40M	$138.70M	$139.00M	$152.15M	$162.42M	$183.29M	$186.34M	$193.37M	$193.87M	$203.06M	$212.58M	$235.58M
Collaborative and Royalty	-	-	-	-	-	-	-	-	-	-	-	-	$900.00K	-	-	-	-	-	-	-
TRIKAFTA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$917.72M	$895.23M	-
Product	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.41B

Vertex Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: TRIKAFTA/KAFTRIO (100.00%).

Vertex Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
UNITED STATES	$6.04B	$5.70B	$5.29B	$4.83B	$3.06B
Outside the United States	$3.83B	$3.23B	$2.29B	$1.38B	$1.10B
Other Countries Outside of the United States and Europe	$719.80M	$525.90M	$313.20M	$249.94M	$214.50M
Europe	$3.11B	$2.71B	$1.97B	$1.13B	$885.76M
Non-US	$4.55B	-	-	-	-

Vertex Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (33.10%), Non-US (24.93%), Outside the United States (20.98%), Europe (17.04%), and Other Countries Outside of the United States and Europe (3.94%).

Quarterly Revenue by Country

Country	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Sep 22	Jun 22	Mar 22	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
UNITED STATES	$1.71B	$1.61B	$1.52B	$1.57B	$1.55B	$1.51B	$1.40B	$1.46B	$1.42B	$1.37B	$1.38B	$1.26B	$1.25B	$1.21B	$1.22B	$1.21B	$1.19B	$1.01B	$710.32M	$700.62M
Other, Non U.S.	$210.70M	$224.50M	$203.30M	$162.80M	$185.40M	$163.80M	$148.20M	$125.60M	$97.00M	$82.45M	$77.54M	$64.90M	$62.34M	$56.49M	$70.13M	$54.66M	$60.48M	-	-	-
Europe	$847.70M	$806.80M	$967.40M	$735.30M	$766.50M	$800.00M	$807.20M	$730.50M	$655.50M	$632.30M	$518.83M	$458.91M	$404.97M	$360.02M	$251.37M	$257.68M	$257.39M	$352.95M	$184.84M	$180.20M
Non-US	$1.06B	$1.03B	$1.17B	$929.30M	$985.40M	$971.00M	$878.70M	$781.10M	$729.30M	$601.27M	$536.45M	$469.87M	$313.71M	$314.17M	$327.52M	$239.50M	$240.68M	-	-	-

Vertex Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (44.74%), Non-US (27.63%), Europe (22.13%), and Other, Non U.S. (5.50%).

Vertex Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
REGN	Regeneron Pharmaceuticals	$13.12B	$3.72B
VRTX	Vertex Pharmaceuticals	$9.84B	$2.77B
MRNA	Moderna	$6.85B	$1.85B
BNTX	BioNTech SE	$3.82B	$187.60M
BMRN	BioMarin Pharmaceutical	$2.42B	$733.87B
ALNY	Alnylam Pharmaceuticals	$1.83B	$420.15M
SRPT	Sarepta Therapeutics	$1.24B	$362.93M
PTCT	PTC Therapeutics	$937.82M	$135.42M
BEAM	Beam Therapeutics	$377.71M	$14.27M
CRSP	CRISPR Therapeutics	$370.00M	$602.00K
DNA	Genie Energy	$251.46M	$89.05M
KRYS	Krystal Biotech	$50.70M	$83.84M
NTLA	Intellia Therapeutics	$36.27M	$9.11M
CRBU	Caribou Biosciences	$34.48M	$3.46M
VERV	Verve Therapeutics	$11.76M	$6.87M
EDIT	Editas Medicine	-	-
VKTX	Viking Therapeutics	-	-
MDGL	Madrigal Pharmaceuticals	-	$62.17M

VRTX Revenue FAQ

What is Vertex Pharmaceuticals’s yearly revenue?

Vertex Pharmaceuticals's yearly revenue for 2023 was $9.84B, representing an increase of 10.17% compared to 2022. The company's yearly revenue for 2022 was $8.93B, representing an increase of 17.91% compared to 2021. VRTX's yearly revenue for 2021 was $7.57B, representing an increase of 22.06% compared to 2020.

What is Vertex Pharmaceuticals’s quarterly revenue?

Vertex Pharmaceuticals's quarterly revenue for Q3 2024 was $2.77B, a 5.21% increase from the previous quarter (Q2 2024), and a 11.61% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $2.63B, a -1.95% decrease from the previous quarter (Q1 2024), and a 5.68% increase year-over-year (Q2 2023). VRTX's quarterly revenue for Q1 2024 was $2.69B, a 6.73% increase from the previous quarter (Q4 2023), and a 13.15% increase year-over-year (Q1 2023).

What is Vertex Pharmaceuticals’s revenue growth rate?

Vertex Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 29.90%, and for the last 5 years (2019-2023) was 136.35%.

What are Vertex Pharmaceuticals’s revenue streams?

Vertex Pharmaceuticals's revenue streams in c 23 are SYMDEKO/SYMKEVI, TRIKAFTA/KAFTRIO, KALYDECO, ORKAMBI, and Product. SYMDEKO/SYMKEVI generated $123M in revenue, accounting 0.62% of the company's total revenue, down -31.67% year-over-year. TRIKAFTA/KAFTRIO generated $8.94B in revenue, accounting 45.32% of the company's total revenue, up 16.36% year-over-year. KALYDECO generated $475.5M in revenue, accounting 2.41% of the company's total revenue, down -14.05% year-over-year. ORKAMBI generated $326M in revenue, accounting 1.65% of the company's total revenue, down -36.17% year-over-year. Product generated $9.87B in revenue, accounting 50.00% of the company's total revenue, up 137.20% year-over-year.

What is Vertex Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Vertex Pharmaceuticals was Product. This segment made a revenue of $9.87B, representing 50.00% of the company's total revenue.